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Abstract
Background: The development and progression of colorectal cancer has been extensively studied and the genes 
responsible have been well characterized. However the correlation between the SMAD4 gene mutations with KRAS 
mutant status has not been explored by many studies so far. Here, in this study we aimed to investigate the role of 
SMAD4 gene aberrations in the pathogenesis of CRC in Kashmir valley and to correlate it with various 
clinicopathological variables and KRAS mutant genotype.
Methods: We examined the paired tumor and normal tissue specimens of 86 CRC patients for the occurrence of 
aberrations in MCR region of SMAD4 and exon 1 of KRAS by PCR-SSCP and/or PCR-Direct sequencing.
Results: The overall mutation rate of mutation cluster region (MCR) region of SMAD4 gene among 86 patients was 
18.6% (16 of 86). 68.75% (11/16) of the SMAD4 gene mutants were found to have mutations in KRAS gene as well. The 
association between the KRAS mutant genotype with SMAD4 mutants was found to be significant (P =< 0.05). Further 
more, we found a significant association of tumor location, tumor grade, node status, occupational exposure to 
pesticides and bleeding PR/Constipation with the mutation status of the SMAD4 gene (P =< 0.05).
Conclusion: Our study suggests that SMAD4 gene aberrations are the common event in CRC development but play a 
differential role in the progression of CRC in higher tumor grade (C+D) and its association with the KRAS mutant status 
suggest that these two molecules together are responsible for the progression of the tumor to higher/advanced stage.
Background
Colorectal carcinoma (CRC) is a common disease in both
men and women worldwide. CRC is the third most com-
mon cause of cancer-related death in the western world
and so is its incidence in Kashmir [1,2]. The majority of
CRCs develop from benign pre-neoplastic lesions: the
adenomatous polyps or adenomas. Progression from a
benign adenoma to a malignant carcinoma passes
through a series of well-defined histological stages, which
is referred to as the adenoma-carcinoma sequence [3].
Two major mechanisms of genomic instability have been
identified that give rise to colorectal carcinoma develop-
ment and progression: chromosomal instability (CIN)
and microsatellite instability (MIN). CIN is associated
with a series of genetic changes that involve the activation
of oncogenes as KRAS and inactivation of tumor suppres-
sor genes as TP53,  SMAD4/DPC4  and  APC, while as
MIN is associated with mutations in DNA mismatch
repair (MMR) genes which affect DNA replication in
repetitive sequences (microsatellites), resulting in an
accumulation of frameshift mutations in genes that con-
tain microsatellites [4-6].
The discovery of human homologues of the Drosophila
Mad gene, called SMAD genes [7], has been a milestone
for understanding the genetics of the CRC whether of
familial origin or sporadic, that has opened the Pandora's
Box for both developmental and cancer biologists. Muta-
tions in two Smad family member genes - SMAD4 (also
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known as MADH4, DPC4 &JIP) and SMAD2 (also known
MADR2, and hMAD-2) have been identified in human
cancers and more importantly with high frequency in
pancreatic and CRCs [8]. This raises the possibility that
one or more of these genes can act as tumor suppressors
as well as developmental regulators. Approximately 50%
of pancreatic carcinomas, 20% of colon carcinomas, and
10% of lung cancers exhibit mutations in SMAD4, and
mutations in SMAD2 have been found in ~7% of colorec-
tal and lung cancers [7,9].
SMAD4 gene is located on the long arm (q) of chromo-
some 18 at band 21.1. The gene encompasses 49.5 kb of
DNA with 13 exons, the first two constituting 5'-UTR as
they do not code for any protein. SMAD4 mRNA tran-
script constitutes 3220 nucleotides [10]. The protein of
SMAD4 gene - Smad4 belongs to the Darfwin family of
proteins which harbors two conserved amino- and car-
boxyl-terminal domains known as MH1 and MH2,
respectively. Smad4 in the basal state is found mostly as a
homo-oligomer, most likely a trimer. It is ubiquitously
expressed within the human body. Smad4 is an intracellu-
lar mediator of TGF-β family and activin type 1 receptor.
Smad4 mediate TGF-β signaling to regulate cell growth
and differentiation. TGF-β stimulation leads to phospho-
rylation and activation of Smad2 and Smad3, which form
complexes with Smad4 that accumulate in the nucleus
and regulate transcription of target genes. By interacting
with DNA-binding proteins, Smad complexes then posi-
tively or negatively regulate the transcription of target
genes [11-13].
Considering the important role of SMAD4 gene in the
colorectal carcinogenesis, we devised our study analyze
the role of SMAD4 gene aberrations in the pathogenesis
of CRC in Kashmir valley and correlate it with various
clinicopathological variables and KRAS mutant genotype.
Methods
Patients and specimens
Out of 124 patients who were diagnosed with colorectal
carcinoma (CRC) by clinicians using either sigmoidscopy
or colonoscopy and confirmed by MRI, a total of 86 col-
orectal cancer tissue specimens comprising tumor tissues
and the corresponding adjacent normal tissues as con-
trols were collected for analysis in this study. All samples
were surgically resected and were collected fresh at the
Department of Surgery of Sher-I-Kashmir Institute of
Medical Sciences, Srinagar, Kashmir. Tissue samples were
divided into two parts; one part was sent to histopatho-
logical diagnosis and other half was stored at -70°C for
molecular investigations. Only histopathologically con-
firmed cases were included for molecular analysis. The
specimens (both tumor and adjacent normal) were snap-
frozen at -70°C immediately until further analysis. No fol-
low up of the CRC patients was carried out after the cura-
tive surgery. Written informed consent was obtained
from all the subjects (and or guardian) included in the
study was taken on pre-designed questionnaire (Available
on request) and was carried out in accordance with the
principles of the Helsinki Declaration. The study protocol
was approved by the Research Ethics Committee of Sher-
I-Kashmir Institute of Medical Sciences, Kashmir.
DNA isolation
Genomic DNA was extracted from blood and tissue sam-
ples (previously stored in -70°C) of colorectal cancer
patients using DNA Extraction Kit II (Zymo Research,
USA) for examining mutations in MCR region (exon 2, 8-
11) of SMAD4 gene and exon 1 of KRAS gene. The tissue
for DNA extraction from tumor sample was chosen by
experienced pathologist and was ascertained to contain
more than 90% of the tumor cells.
PCR-SSCP analysis
The SMAD4 and KRAS gene analysis was done on all the
extracted DNA samples. The MCR region of SMAD4
gene comprising of exons 2, 8, 9, 10 and 11 and exon 1 of
KRAS  were amplified using specific oligonucleotide
primers [Table 1] [Additional file 1]. PCR was performed
in a 25 μl total volume reaction mixture containing 50 ng
of genomic DNA, 100 ng of each primer, 100 μM of each
dNTP, 1.5 mM MgCl2, 10× of Taq buffer and 1 U of Taq
DNA polymerase (Genie, India). The conditions of PCR
were as: initial denaturation at 95°C for 5 min, 35 cycles
of denaturation at 95°C, annealing at X°C [Table 1] and
extension at 72°C, for 30 seconds each and final extension
at 72°C for 7 min in Biorad icycler. The PCR products
were run on 2% agarose gel and analyzed under UV illu-
minator.
SSCP analysis of PCR product was carried out on 6%
non-denaturing Polyacrylamide gel (PAG) utilizing either
non-radioactive silver staining or radioactive procedures
[14-16] [Additional file 1]. In non-radioactive SSCP anal-
ysis, PCR products mixed in denaturing buffer (95% for-
mamide, 10 mM NaOH, 0.05% xylene-cyanol FF and
0.05% bromophenol blue) in 1:1 ratio were heat dena-
tured at 95°C for 5 min, immediately cooled on ice for 20
min, 6 μl of which were loaded on 6% PAG and eletro-
phoresed in 0.5× Tris-borate EDTA buffer at ± 17°C at 4
W constant power for 18-22 h. Gels were then silver
stained. In radioactive SSCP analysis, radio labeled PCR
products (using α32-pCTP) mixed in denaturing loading
buffer (95% formamide, 20 mM EDTA, 0.05% xylene-
cyanol FF and 0.05% (bromophenol blue) in 1:10 ratio
were heat denatured at 95°C for 5 min, 3 μl of which were
loaded on 6% PAG and electrophoresed at 4 W in 0.5×
Tris-borate EDTA buffer at ± 17°C for 18-22 h. Gel was
then transferred onto 3 mm Whatmann paper, covered
with saran wrap and dried in vacuum drier at 90°C for 1Sameer et al. BMC Cancer 2010, 10:300
http://www.biomedcentral.com/1471-2407/10/300
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h. The saran wrap was then replaced by X-ray film and
kept at -70°C for 48 h.
The mobility shift in DNA bands were visualized by
developing the X-ray film in a developer. Purified PCR
products of the samples showing mobility shift on SSCP
analysis and randomly chosen samples were used for
direct DNA sequencing.
Direct Sequencing
PCR amplicons of the tumor samples and from randomly
chosen normal samples were first purified by DNA recov-
ery kit (Zymo Research, USA) and then used for direct
DNA sequencing. DNA sequencing was carried out at
MACROGEN INC, Korea. To minimize the sequencing
artifacts by PCR, amplicons from at least two different
PCRs were sequenced using forward and reverse primers.
Statistical Analysis
All statistical analysis was performed using PASW, Ver-
sion 18 (IBM, USA). Pearson's chi-square two-proportion
test was used to evaluate the hypothesis of equal distribu-
tion of molecular alterations in different clinic-pathologi-
cal variables. A chi-square probability (P values) of 0.05
or less was considered to be statistically significant. No
adjustment was made for performing multiple tests.
Results
Out of 86 confirmed cases of CRC, 38 were of Duke's
A+B Stage and 48 were of Stage C+D. All of them pre-
s e n t e d  c o n s t i p a t i o n  a n d  b l e e d i n g  p e r  r e c t u m  a s  t h e i r
chief complaint. Further more, out of 86 confirmed cases
of CRC, 81 cases were sporadic, 4 were FAP and one case
was Lynch Syndrome. All but one case were adenocarci-
noma and only one was squamous cell carcinoma (SCC)
of basal cell type. 37 cases were females and 49 males, 59
rural and 27 urban, 36 cases had carcinoma in colon and
50 in rectum and 55 were smokers and 31 non smokers
[Table 2].
The overall mutation rate of mutation cluster region
(MCR) of SMAD4 gene among 86 patients was 18.6% (16
of 86) [Table 2, Figure 1 &2]. 68.75% (11/16) of the
SMAD4 gene mutants were found to have mutations in
KRAS gene as well, the data (of KRAS mutations only) has
been previously declared by our lab in two studies [14,15]
by Sameer et al, 2009. Out of 11 KRAS mutants seven had
mutations that has been reported already by our lab. In
addition to those we also found two new novel mutations
in KRAS oncogene in new procured tumor tissue sam-
ples. One was the A:T > T:A transversion of in codon 16
resulting in the truncation (AAG > TAG; Lys > Stop) of
Kras protein in two tumor tissues and second was the C:T
> T:C transition at codon 19 leading to change of leucine
to phenaylalanine (CTT > TTT) in two tumor tissues
[Table 2, Figures 3 &4]. In Total 21 of 86 (24.4%) tumor
tissues had mutant KRAS gene out of these 21, 11 (52.4%)
were SMAD4 gene mutants [Table 3 &4]. There were 9
(56.25%) tumors which had both KRAS activating muta-
tions as well as SMAD4 single point mutations. Further-
more, in case of advanced/higher grade tumors (C+D =
48),  KRAS gene mutations was found 15 (31.25%) and
SMAD4 gene was found to be mutated in 14 (29.2%)
tumors. Also, 9 (18.75%) of C + D grade tumors had
Table 1: Specific primers for SMAD4 mutational analysis
Gene/Exon Sequence Amplicon Size (bp) Tm (oC)
SMAD4/Ex 2 F 5'-TTC TAGGTG GCT GGT CGG AA-3'
R 5'-CAG GTG ATA CAA CTC GTT CG-3'
175 56
SMAD4/Ex 8 F 5'-TTT CTC ATG GGA GGA TGT TC-3'
R 5'-CAA TTT TTT AAA GTA ACT ATC TGA C-3'
264 57
SMAD4/Ex 9 F 5'- TAT TAA GCA TGC TAT ACA ATC TG -3'
R 5'- CTT CCA CCC AGA TTT CAA TTC -3'
332 58
SMAD4/Ex 10 F 5'-GAA TTT TCT TTA TGA ACT CAT AG-3'
R 5'-TTT AAA AAA GAA TGA AAA GCA TAC-3'
213 57
SMAD4/Ex 11 F 5'-CTG ATG TCT TCC AAA CTC TTT TCT G-3'
R 5'-TGT ATT TTG TAG TCC ACC ATC-3'
299 57
KRAS/Ex1 F: 5'-CTG CTG AAA ATG ACT GAA TA-3'
R: 5'-ATG GTC CTG CAC CAG TAA TA-3'
162 48
Yakicier MC et al; Oncogene. 1999: 18: 4879-83.
Hadžija MP et al; Mutation Research. 2004; 548: 61-73.
Sameer AS et al; Saudi J Gastroenterol. 2009; 15: 244-252.S
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Table 2: Nature of SMAD4 MCR region mutations in 86 colorectal carcinoma patients from Kashmir valley
Patient ID Age/Sexa Dwellingb Duke's 
Stagec
Smoking 
Statusd
Node 
Statuse
Sitef Natureg Pesticide 
Exposure
SMAD
4 Exon
Mutationh Amino Acid 
Change
Affected 
Codon
Effecti KRAS Status/
Affected Codon
X01 55/M R A NSk N C LS Y 2 TGT > CGT Cys > Arg 115 MS M; 12 Gly > Asp
X06 28/M R C Sk Y R S Y 8 CGC > AGC Arg > Ser 361 MS W
X12 65/F R C Sk Y C S Y 10 CAG > TAG Gln > Stop 442 NS W
X16 62/F U C Sk Y C S N 8 CGC > CACA r g  >  H i s 3 6 1 M S W
X17 67/F R D Sk Y R S Y 8 TTT>TTG Phe > Leu 362 MS M; 12 Gly > Asp
X30 44/F R D Sk Y C S Y 8 TGT > AGT Cys > Ser 363 MS M; 12 Gly > Asp
X31 64/M R C Sk Y C FAP Y 8 GGT > GATG l y  >  A s p3 4 1 M S W
X43 80/F U D Sk Y R S Y 10 GCT>GCC Ala >Ala 456 S W
X47 60/F R B Sk N C S Y 11 AAAGGC > AATTGC Lys > Asn; Gly > Cys 507/8 MS M; 13 Gly > Cys
X51 58/M R C Sk Y C S Y 11 GGC > AGC Gly > Ser 508 MS M; 12 Gly > Ser
X56 45/M U D Sk Y R S Y 9 TGG > GGG Trp > Gly 419 MS M; 19 Leu > Phe
X57 40/M R D Sk Y C FAP N 9 AGACAGAG > AGAG Deletion 415/16 << FS M; 16 Lys > Stop
X65 43/M R C NSk Y C S Y 8 CGC > CAC Arg > His 361 MS M; 19 Leu > Phe
X75 55/F R C NSk Y C S Y 11 AAA > CAA Lys > Gln 507 MS M; 13 Gly > Arg
X85 38/M U C Sk Y C S N 9 AGA > AAA Arg > Lys 415 MS M; 16 Lys > Stop
X86 60/M R D Sk Y C S Y 10 CGA > TGA Arg > Stop 445 NS M; 12 Gly > Ala
aAge/Sex: M = Male, F = Female; bDwelling: R = Rural, U = Urban; cDuke's stage: A - Tumor confined to the intestinal wall; B - Tumor invading through the intestinal wall; C - With lymph node(s) 
involvement; D - With distant metastasis; dSmoking Status: Sk: Smokers; NSk: Non Smokers; eNode Status: N = Negative, P = Positive; fSite of tumor: C = Colon, R = Rectum; gNature of tumor: S: 
Sporadic; LS: Lynch Syndrome; FAP: Familial Adenomatous Polyposis; hMutation: Mutated or inserted nucleotide underlined; hMutation Effect: MS: Missense mutation; NS: Nonsense mutation; S: 
Silent mutation; FS: Frameshift mutation.Sameer et al. BMC Cancer 2010, 10:300
http://www.biomedcentral.com/1471-2407/10/300
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Table 3: Clinico-epidemiological variables of the 86 colorectal carcinoma patients versus 16 mutant phenotypes of SMAD4 
gene
Variable Total N = 86 Mutants M = 16 (18.6%) P value*
Age group
≤60 52(60.5%) 11(21.2%) NS
>60 34(39.5%) 5(14.7%)
Gender
Female 37 (43.0%) 7 (18.9%) NS
Male 49 (67.0%) 9 (18.4%)
Dwelling
Rural 59 (68.6%) 12 (20.3%) NS
Urban 27 (31.4%) 4 (14.8%)
Tumor location
Colon 36 (41.9%) 12 (33.3%) <0.01
Rectum 50 (58.1%) 4 (8.0%
Nodal status
Involved 48 (55.8%) 14 (29.2%) <0.01
Not Involved 38 (44.2%) 2 (5.3%)
Tumor grade
A + B 38 (44.2%) 2 (5.3%) <0.01
C + D 48 (55.8%) 14 (29.2%)
Smoking status
Ever 55 (64.0%) 13 (23.6%) NS
Never 31 (36.0%) 3 (9.6%)
Bleeding PR/Constipation
Yes 60 (69.8%) 15 (25.0%) <0.01
No 26 (30.2%) 1 (3.8%)
Pesticide Exposure
Ever 53 (61.6%) 13 (24.5%) <0.05
Never 33 (38.4%) 3 (9.1%)
KRAS Status
Wild-type 65 (75.6%) 5 (7.7%) < 0.01
Mutated 21 (24.4%) 11 (52.4%)
*Pearson's two proportion testSameer et al. BMC Cancer 2010, 10:300
http://www.biomedcentral.com/1471-2407/10/300
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mutations in both KRAS as well as SMAD4 gene as com-
pared to only 2 (5.2%) of A+B grade tumors [Table 4 &5].
The mutant status of KRAS and SMAD4 gene was found
to be significantly associated with the higher tumor grade
(C+D) (P value = 0.03).
Analysis of the mutation spectrum of MCR region of
SMAD4 gene revealed 16 mutations in total. There were
twelve missense mutations, two nonsense mutations, one
silent mutation and one frameshift mutation - including
nine transitions and four transversions. The frame shift
mutation was observed in codons 415/416 (exon 9) due to
deletion of AGACA pentamer [Table 2, Figure 2]. Among
the transistions, G:A > A:G substitutions were most prev-
alent followed by C:T > T:C. The two nonsense mutations
included, CAG > TAG transition leading to Gln > Stop at
codon 442 and other CGA > TGA transition leading to
Arg > Stop at codon 445, both occurred in exon 10 of
SMAD4 gene [Table 2, Figure 1].
A number of salient and interesting features were found
to be associated with the SMAD4 gene mutants, Among
the 16 mutations seen, there were one (6.25%) in exon 2,
six (37.5%) in exon 8, three (18.75%) each in exon 9, exon
10, and exon 11 of MCR region of SMAD4 gene [Table 2].
Clearly the hot spot exon within the MCR region of the
SMAD4 gene was exon 8 and within the exon 8 it was the
codon 361 which was frequently aberrated due to muta-
tions. Out of 16 SMAD4 mutants two (X31 & X57) were
of FAP nature, one was LS (X01) and 13 remaining were
of sporadic nature [Table 2].
Further more, we found a significant association of
Tumor location, Nodal status and Bleeding PR/Constipa-
tion with the mutation status of the SMAD4 gene (P =<
0.05). We also found association between the occupa-
tional exposure to pesticides with that of the mutant sta-
tus of SMAD4  gene (P =< 0.05) identifying it as a
potential risk factor. There was also a significant associa-
tion of the SMAD4 mutants with KRAS mutants [Table
3].
Discussion
Kashmir valley located in the northern division of India,
surrounded by Himalayas has an unique ethnic popula-
tion living in a temperate environmental conditions hav-
ing distinctive food habits which play an overwhelming
role in the development of GIT cancers over the genetic
factors [17-19]. The food habits include consumption of
sun-dried and smoked fish and meat, dried and pickled
Table 4: Correlation of SMAD4 gene status versus KRAS gene status
SMAD4 Status
Wild N = 70 Mutant M = 16 OR; P Value; CI (95%)
KRAS Status
Wild; n = 65 60 (92.3%) 5 (7.7%) 0.07; 0.00003; 0.021- 0.26
Mutant; n = 21 10 (47.6%) 11(52.4%)
Figure 1 Partial nucleotide sequence representing the mutant 
(Above) and normal (Below) {Shown by asterik and arrows}, of 
MCR region of SMAD4 gene. 1A: Transition of G > A at codon 341; 
GGT > GAT; Gly > Asp in Exon8 of SMAD4 gene. 1B: Transition of G > A 
at codon 361; CGC > CAC; Arg > His in Exon8 of SMAD4 gene. 1C: Trans-
version of T > G at codon 362; TTT > TTG; Phe > Leu in Exon8 of SMAD4 
gene. 1D: Transition of G > A at Codon 415; AGA > AAA; Arg > Lys in 
Exon9 of SMAD4 gene1E: Transversion of T > G at codon 419; TGG > 
GGG; Trp > Gly in Exon9 of SMAD4 gene
Figure 2 Partial nucleotide sequence representing the mutant 
(Above) and normal (Below) {Shown by asterik and arrows}, of 
Deletion of AGACA pentamer at codons 415/416 in Exon9 (MCR) 
of SMAD4 geneSameer et al. BMC Cancer 2010, 10:300
http://www.biomedcentral.com/1471-2407/10/300
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vegetables, red chilly, Hakh (a leafy vegetable of Brassica
family), hot noon chai (salted tea) and Hukka (water pipe)
smoke [20]. As previously reported [21], the etiology and
incidence of various GIT cancers in this population has
been attributed to a probable exposure to nitroso com-
pounds, amines and nitrates reported to be present in
these local food stuffs.
Colorectal cancer being the commonest cancer, is the
major cause of mortality and morbidity worldwide, there
are nearly one million new cases of colorectal cancer
diagnosed world-wide each year and half a million deaths
[22]. The incidence of this malignancy shows consider-
able variation among racially or ethnically defined popu-
lations in multiracial/ethnic countries. Kashmir has been
reported by now as a high-incidence area of GIT cancers
[19,20]. Colorectal Cancer in Kashmir valley is the third
most common GIT cancer after esophageal and gastric as
per SKIMS Medical record registry, with almost over 124
cases reported by the end of year 2009.
Among the most common genetic abnormalities in col-
orectal carcinomas, deletions in the long arm of chromo-
some 18 are the foremost one [3]. A number of different
genes have been shown to be the target of these deletions,
which include APC and SMAD2 and SMAD4 - the two
genes of the TGF-β signal transduction cascade [23].
TGF-β signaling is an important regulator of prolifera-
tion, differentiation, and apoptosis with a key role in non-
transformed human colon epithelium homeostasis
[24,25]. The SMAD4 gene - already identified as a candi-
date tumor suppressor gene for pancreatic cancers [7]
located at 18q21.1 in close proximity to APC, has recently
attracted considerable interest as a prime candidate tar-
get gene for the 18q deletions because of recent data link-
ing mutations in this gene to sporadic and familial
colorectal cancer [26,27].
TGF-β signaling regulates tumorigenesis and in human
cancer its signaling pathways are often modified during
tumor progression [28]. The growth inhibitory effect of
TGF-β signaling in epithelial cells explains its role as a
tumor suppressor in carcinomas, although TGF-β expres-
sion by tumor cells contributes to cancer progression as
well [29,30] thus unlike other signaling pathways it plays a
dual role [31]. Smads are the key intracellular mediators
of transcriptional responses to TGF-β signaling, and
among these Smad4 is the pivotal factor of the TGF-β
pathway as it functions as a key tumor suppressor [24-
26,29-31]. The role of Smad4 gene as an important tumor
suppressor gene came out by the novel study of the allelo-
type loss in pancreatic adenocarcinoma [32]. This study
showed that about 90% of these tumors show allelic loss
of chromosome 18q. In the same year another study iden-
tified the genetic target of these allelic losses as the
SMAD4/DPC4 gene (DPC-Deleted in Pancreatic Carci-
noma, locus 4). The study analyzed 338 tumors, originat-
ing from 12 distinct anatomic sites, for alterations in the
SMAD4/DPC4 gene. An alteration of the SMAD4/DPC4
gene sequence was identified in one of eight breast carci-
nomas and one of eight ovarian carcinomas. SMAD4/
DPC4 was found to be homozygously deleted in about
30% of pancreatic carcinomas and inactivated by
intragenic mutation in another 20% of the tumors. The
tissue restriction of alterations in SMAD4/DPC4, as in
many other tumor-suppressor genes, emphasizes the
complexity of rate-limiting checkpoints in human tum-
origenesis [33]. Most of Smad4 gene mutations in human
cancer are missense, nonsense, and frameshift mutations
Figure 3 Partial nucleotide sequence (reverse) representing the 
mutant (A) and normal (B) {Shown by asterik and arrows}, of KRAS 
exon 1 gene. 3A: Transition of C > T at codon 19; CTT > TTT; Leu > Phe 
in Exon 1 of KRAS oncogene. 3B: Transversion of A > T at codon 16; AAG 
> TAG; Lys > Stop in Exon 1 of KRAS oncogene
Figure 4 Partial nucleotide sequence (reverse) representing the 
mutant (A) and normal (B) {Shown by asterik and arrows}, of KRAS 
exon 1 gene. 4A: Transition of G > A at codon 12; to GGT > GAT; Gly > 
Asp in Exon 1 of KRAS oncogene. 4B: Transversion of G > T at codon 12; 
GGT > TGT; Gly > Cys in Exon 1 of KRAS oncogene. 4C: Transversion of 
G > C at codon 12; GGT > GCT; Gly > Ala in Exon 1 of KRAS oncogeneSameer et al. BMC Cancer 2010, 10:300
http://www.biomedcentral.com/1471-2407/10/300
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at the mad homology 2 region (MH2) which interfere
with the homo-oligomer formation of Smad4 protein and
hetero-oligomer formation between Smad4 and Smad2
proteins, resulting in disruption of TGF-β signaling
[12,26,33-35].
Our study was carried out to clarify the involvement of
SMAD4 in the development and progression of colorectal
carcinoma where it is reported to be mutated or deleted
in about 20% of invasive cases [26] and the relationship
between the mutant status of SMAD4 and KRAS genes.
We found that 15 out of 16 mutations of SMAD4 gene
occurred in C-terminal region of SMAD4  gene which
codes for MH2 domain of Smad protein. These results
are in conformation with the previous studies [26,27,36]
carried out on this gene. The MH2 domain of Smad4 pro-
tein is a multifunctional region that mediates differential
association with a wide variety of proteins. Many of these
interactions serve to provide specificity and selectivity to
Smad function. The Smads exist as monomers and trim-
ers, and through various studies it is clear that the MH2
domain is critical for mediating interactions in the oli-
gomers [12]. The mutations in this region henceforth are
deleterious to the overall interaction of Smad protein
with itself and with other downstream proteins, thereby
affecting the signal transduction of TGF-β pathway and
hence hampering normal colonic mucosal cell develop-
ment and differentiation. Furthermore, in a recent study
by Zhang et al, 2009 on transgenic mice [37] it was found
beyond doubt that wild smad4 protein played an impor-
tant anti-metastatic role in the development and progres-
sion of CRC. It was also found in this seminal study that
loss of Smad4 in MC38 cells plays an important role in
increasing the tumorigenic and metastatic potential of
these cells as the loss of smad4 protein appears to switch
TGF-β from a tumor suppressor to a tumor promoter
pathway.
Another salient feature of the mutations found in this
study was the deletion of AGACA pentamer in exon 9 of
the  SMAD4  gene in one tumor tissue from a Familial
Adenomatous Polyposis case [Figure 2]. This affected
codon is 415/16 of the SMAD4 gene reflecting its effect
on MH2 domain of Smad4 protein. Similar type of dele-
tion has also been reported previously by Miyaki et al,
1999 in Familial Adenomatous Polyposis (FAP) tumors
within the same region of the SMAD4 gene [26]. Also,
this tumor tissue was found to be KRAS mutant. The two
nonsense mutations found in this study - one affecting
codon 442 (Gln > Stop) and other codon 445 (Arg > Stop)
occurred in exon 10 of SMAD4 gene. Both of these muta-
tions lead to the synthesis of truncated Smad4 protein
devoid of oligomerisation properties. One of these
mutant tumors was found to be KRAS mutant at codon
12 (Gly > Ala) as well [Figure 3 &4].
We also assessed the relationship between the TGF-β
pathway and MAP Kinase pathway via SMAD4 and KRAS
proteins. We found that 21 out of 86 (24.4%) tumors were
KRAS mutants, and out of 16 SMAD4 mutants 11 (52.4%)
were  KRAS  mutants also. The cross talk mechanism
between these two pathways has been experimented
upon and conceptualized previously [38]. Cross-talk
between RAS and TGF-β signaling has been reported to
play important roles in various physiological and patho-
logical processes, and RAS signal has been reported to
regulate TGF-β signaling both positively and negatively
[39]. RAS transformation in lung, intestinal, liver, pan-
creas, and mammary epithelial cells has been reported to
confer resistance to growth inhibition by TGF-β [40-42].
We found a significant association between the mutant
statuses of the SMAD4 gene with that of the KRAS gene,
thereby suggesting that similar mechanisms in our popu-
lation where a cross talk between the MAP Kinase and
TGF-β pathways might play a role in the development of
CRC to advanced stage cumulatively [38,39,43] as we
found 29 (60.4%) of higher grade tumors (C+D) were
mutants for either of the two genes (KRAS and SMAD4)
[Table 5]. Also, we found that 9/11 (81.8%) of the both
gene mutants belonged to C+D tumor grade category.
This observation clearly suggested a link between these
two important cell development controlling genes. In
other words we can say that the tumor which has SMAD4
mutant status is also likely to have KRAS gene mutant
status. Janda et al, 2002 [44] reported that hyperactiva-
tion of the Raf-MAP kinase pathway synergizes with
TGF-β signaling and induces epithelial-mesenchymal
transition (EMT) and accelerates the tumorigenesis and
metastasis of the otherwise normal cells. EMT has been
Table 5: Correlation of tumor grade versus SMAD4 gene status versus KRAS gene status
Mutants
KRAS N = 21 SMAD4 N = 16 χ2, P value Both N = 11
Tumor Grade
A + B = 38 6 (28.6%) 2 (12.5%) 2 (18.2%)
C + D = 48 15 (71.4%) 14 (87.5%) 6.63, 0.03 9 (81.8%)
OR = 0.28; 95% CI = 0.05-1.37Sameer et al. BMC Cancer 2010, 10:300
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found to be an important tread in the invasion and
metastasis of cancer and TGF-β prominently induces
progression of cancer through EMT [45].
In a seminal study by Bardeesy et al, 2006 [46] on genet-
ically engineered mice the impact of SMAD4 deficiency
on the initiation, development and/or progression of pan-
creatic ductal adenocarcinoma (PDAC) was ascertained.
It was observed that selective SMAD4  deletion in the
pancreatic epithelium had no discernable impact on pan-
creatic development or physiology, but when combined
with the activated KRASG12D allele,  SMAD4  deficiency
enabled rapid progression of KRASG12D-initiated neo-
plasms. The study concluded that SMAD4  is a PDAC
tumor suppressor, functioning to block the progression of
KRASG12D-initiated neoplasm's. In another similar study
by Izeradjene et al, 2007 [47] on various molecular
aspects on invasive adenocarcinoma of pancreas, it was
revealed that KRASG12D tumors had higher chances of
developing the SMAD4 haplo-insufficiency, which in turn
leads to invasiveness of the tumor.
As reported by many authors, the substitutions of
codon 12 and 13 are predominant mutations in KRAS
gene [48,49]. These amino-acid substitutions in KRAS
alters its GTPase activity to a different extent and/or its
ability to interact with its regulators, depending upon the
substituted amino-acid residue [14]. KRASG12V  and
KRASG12R mutants are aggressive transforming pheno-
types, while KRASG12S and KRASG12D have less striking
morphological effects [49]. In addition to the commonly
reported activating mutation our analysis of KRAS gene
also revealed a novel transversion of A > T in codon 16
(Lys > Stop) and an activating mutation in codon 19 (Leu
to Phe). This study is the first to report these two novel
m uta t ions.  Sim ila r ki nd of  m uta t io ns ha ve  bee n pr evi-
ously reported from this part of globe [50], where codons
15, 18, 20 and 30 of KRAS have been implicated in the
tumorigenesis of CRC. Wang et al in their study showed
that codon 15 Kras mutant protein has less GTPase activ-
ity than that of the wild-type Kras protein due to a lack of
response to GAP induction owing to its less sensitivity to
GAP.
Further more, we also found the SMAD4 mutant status
associated with occupational exposure to pesticides, sig-
nifying that pesticides serves as the important risk factor
in the development of CRC like other cancers [Table 3],
as has been previously reported in various studies [51-
53]. This finding was also in tune with the study of Lee et
al, 2007 [54] in which various chemicals present in pesti-
cides were found to be associated with the significant
increased risk of colorectal cancer. In a seminal study by
Blair et al, carried out on pesticide exposure to farmers
indicated that farmers were more favorable to die of dis-
eases including all causes combined, heart disease, as well
as cancers of the lung, bladder, liver, colon, esophagus,
rectum, and kidney. Following the criteria of Teitelbaum
SL, 2002 [55], we also identified pesticide exposure as a
potential risk factor for the development of CRC in Kash-
mir valley, since most of the cases reported in this part of
globe are from rural areas and more importantly people
who are directly or indirectly associated with agriculture
as their main occupation and source of lively hood.
Conclusion
In this novel study, we found that SMAD4 gene aberra-
tions are the common event in CRC development but
play a differential role in the progression of CRC in higher
tumor grade (C + D). We have also observed a statistically
significant association of SMAD4 gene aberrations with
KRAS  mutant status suggesting the involvement of at
least two molecules in the advanced tumor grade in col-
o r e c t a l  c a n c e r s ;  i n  o t h e r  w o r d s ,  i n  c a s e  o f  h i g h  g r a d e
advanced tumor, aberration in more than one molecular
gate keeper of several signal transduction pathways may
be involved.
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